Ibopamine

Ibopamine is a sympathomimetic small molecule drug developed as a prodrug of epinine (N-methyldopamine), primarily used in ophthalmology to induce mydriasis and as a provocative test for glaucoma. It has also been investigated for the treatment of congestive heart failure. After administration, ibopamine is rapidly hydrolyzed by esterases to its active metabolite epinine, which acts as an agonist at D1 and D2 dopaminergic receptors and alpha-adrenergic (alpha 1 and alpha 2) as well as beta-adrenergic (beta 1 and beta 2) receptors. This receptor activity leads to vasodilation, increased cardiac output, increased renal blood flow, mild positive inotropic effects without significant increase in heart rate or myocardial oxygen consumption, and modulation of neuroendocrine reflexes such as reduced plasma renin activity and aldosterone levels. In ophthalmology it induces fast-onset but short-lasting pupil dilation with minimal systemic side effects[1][3][5][6].

Other names

ibopaminoibopaminum66195-31-1